Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group
Modern Pathology · 2024
DOI: 10.1016/j.modpat.2023.100406 ↗Kurz gefasst
Fallbericht in der Zeitschrift Modern Pathology, 2024. Verfasst von Daniel Rivera und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pathology and Laboratory Medicine, Th…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Thrombocytosis, Eosinophilia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is characterized by leukocytosis with left-shifted neutrophilia, basophilia, eosinophilia, and variable thrombocytosis. However, extremely rare cases of patients with CML without significant leukocytosis and thrombocytosis (aleukemic phase [ALP] CML, or CML-ALP) have been reported. Due to its rarity and limited awareness, there remains a significant knowledge gap concerning the pathologic diagnosis, disease progression, and optimal patient management and outcomes. In this multi-institutional study, we investigated 31 patients with CML-ALP. Over half (54.8%) of patients had a history of or concurrent hematopoietic or nonhematopoietic malignancies. At time of diagnosis of CML-ALP, approximately 26.7% of patients exhibited neutrophilia, 56.7% had basophilia, and 13.3% showed eosinophilia. The median number of metaphases positive for t(9;22)(q34;q11.2) was 15, with a median of 38.5% of interphase nuclei positive for BCR::ABL1 by fluorescence in situ hybridization. The median BCR::ABL1 level was 26.14%. Remarkably, 14 (45.2%) patients were initially misdiagnosed or not diagnosed before karyotype or fluorescence in situ hybridization information for BCR::ABL1 became available. Twenty-five patients received tyrosine kinase inhibitors (TKIs). One patient developed blast crisis while on TKI treatment 8 months after initial diagnosis. With a median follow-up time of 46.1 months, 20 of 22 patients who received TKI therapy and had detailed follow-up information achieved complete cytogenetic remission or deeper, 15 achieved major molecular remission or deeper, and 10 achieved molecularly undetectable leukemia. In conclusion, given the frequent occurrence of prior or concurrent malignancies, aleukemic presentation, and low level of t(9;22)(q34;q11.2)/BCR::ABL1, misdiagnosis or delayed diagnosis is common among these patients. While these patients generally respond well to TKIs, rare patients may develop blastic transformation. It is therefore important for pathologists and hematologists to be aware of this highly unusual presentation of CML to ensure timely diagnosis and appropriate management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, Houston, Texas.
- Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas.
- Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.
- Department of Pathology, University of New Mexico, Albuquerque, New Mexico.
- McLaren Health Care, Lansing, Michigan.
Förderung
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Rivera, D., Cui, W., Gao, J., Peker, D., Zhang, Q. Y., Dewar, R., Qiu, L., Konoplev, S., Hu, Z., Sasaki, K., Hu, A. Y., E, S., Liu, M., Fang, H., Wang, W., Tang, G., Apperley, J. F., Hochhaus, A., Cortes, J. E., …, & Hu, S. (2024). Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100406
Vancouver
Rivera D, Cui W, Gao J, Peker D, Zhang QY, Dewar R, et al. Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group. Modern Pathology. 2024. doi:10.1016/j.modpat.2023.100406
BibTeX
@article{Rivera2024,
author = {Rivera, Daniel and Cui, Wei and Gao, Juehua and Peker, Deniz and Zhang, Qian-Yun and Dewar, Rajan and Qiu, Lianqun and Konoplev, Sergej and Hu, Zhihong and Sasaki, Koji and Hu, Aileen Y and E, Shuyu and Liu, Meng and Fang, Hong and Wang, Wei and Tang, Guilin and Apperley, Jane F and Hochhaus, Andreas and Cortes, Jorge E and Khoury, Joseph D and Medeiros, L Jeffrey and Jabbour, Elias and Hu, Shimin},
title = {Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group},
journal = {Modern Pathology},
year = {2024},
doi = {10.1016/j.modpat.2023.100406}
}
EUVIMED